Alaide Morcavallo
Senior Scientist, Research, Bioscience & Oncology AstraZeneca
At AstraZeneca, Dr Alaide Morcavallo provides scientific support to the DNA Damage Response and Epigenetics franchises and serves as Outsourcing Lead for the In Vivo Pharmacology team within Early Oncology Bioscience UK. She has built her career at the interface of oncology research and drug development, with expertise in paediatric brain tumours, translational science, and the development of novel in vivo models to advance therapeutic innovation. Before joining AstraZeneca, she trained at Magna Graecia University in Italy, the Sidney Kimmel Cancer Center in the USA, and the Institute of Cancer Research in the UK. Dr Morcavallo holds a PhD in Molecular Oncology and a mini-MBA.
Seminars
Thursday 3rd December 2026
Evidence – Moving Beyond Data Generation to Strategic CRO Partnerships in Tumour Model Development
3:00 pm
- Evaluating CROs not only on execution, but on their ability to provide scientific insight and study design support
- Avoiding cost driven decisions that compromise data quality and long term development success
- Building effective collaborations that strengthen decision making and improve translational confidence
Thursday 3rd December 2026
Insight Exchange – Building an End-to-End Development Strategy That Delivers Better Decisions
3:20 pm
- Where do development programmes most commonly break down between discovery, translational, clinical, and external partners?
- How early should CROs, translational scientists, and pharmacology teams be involved in model selection decisions?
- What distinguishes a strategic partner from a service provider when generating decision-grade data?
- How can organisations balance speed, cost, scientific rigour, and translational confidence throughout development?
- Audience Q&As
